Trial intelligence / Profile preview

Baclofen add-on for inpatient GHB detoxification

NL-OMON59818Phase 2Recruiting

Sponsor
Radboud University Medical Center
Start
Jun 2025
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, single-arm trial of baclofen in gamma-hydroxybutyrate use disorder (GHBUD), sponsored by Radboud University Medical Center. Primary endpoint: Pharmaceutical GHB dosage at end of titration phase. Started Jun 2025; status: recruiting.

02

Drugs

baclofen
03

Conditions

gamma-hydroxybutyrate use disorder (GHBUD)

Beyond the preview

Go deeper on NL-OMON59818.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON59818.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call